hca glp 1 coverage reddit The evolving landscape of anti-obesity medication in Medicaid California to stop paying insurance

Bottom line Weight loss medications arent for everyone

Isso pode levar reduo da ingesto de alimentos e perda de peso, o que benfico para pacientes com DM2 que tambm enfrentam problemas de obesidade

Clinical Trial Results: Weight Loss & Key Outcomes Phase 2 (Published in NEJM & Nature Medicine) Obesity trial (NEJM 2023): Up to 24.2% mean weight loss at 48 weeks (12 mg dose)

Kelley D., a mom of two in Indiana, used a GLP-1 to help her lose weight (though not in the immediate postpartum period), and while it made a positive impact on her, it wasnt always pleasant

Phase 2 trial (NEJM, 2023) The landmark Phase 2 trial, published in the New England Journal of Medicine, randomized 338 adults with obesity to receive weekly subcutaneous retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg, or placebo, for 48 weeks